Company
BCAL Diagnostics Ltd
Headquarters: Sydney, NSW, Australia
BCAL Diagnostics Ltd Categories
Australia Healthcare Diagnostics & ResearchAustralia Healthcare Australia Diagnostics & Research
Top Competitors by Market Capitalization
Industry: Diagnostics & Research
| Company | Market Cap (USD) |
|---|---|
| Thermo Fisher Scientific | $162.07 B |
| Danaher | $144.92 B |
| Siemens Healthineers AG | $64.17 B |
| Lonza Group Ltd | $49.67 B |
| IDEXX Laboratories, Inc. | $43.99 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
Detailed Description
BCAL Diagnostics Limited, a biotechnology company, engages in developing a non-invasive laboratory blood test for the detection of breast cancer. It develops BCAL test, a lipid biomarker blood test with the potential to be used for breast cancer prevention, screening, and monitoring; and in vitro diagnostic test (IVD) that confirms a fingerprint of lipid biomarkers extracted from extracellular vesicles from a patient's plasma or blood sample to diagnose the presence of breast cancer cells in a patient's body. The company was incorporated in 2010 and is headquartered in Sydney, Australia.
Stocks & Indices
BCAL Diagnostics Ltd has the following listings and related stock indices.
Stock: ASX: BDX wb_incandescent